Interventions to Redesign Patient Care Do Not Improve Outcomes
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Nov. 1, 2023 -- Interventions to redesign care for hospitalized patients are not associated with improved patient outcomes, according to a study published online Oct. 31 in the Annals of Internal Medicine.
Kevin J. O'Leary, M.D., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues examined the effect of interventions to redesign hospital care delivery on teamwork and patient outcomes in a pragmatic controlled trial conducted in medical units at four U.S. hospitals. The primary outcomes were teamwork climate among health care professionals and patient-experienced adverse events.
The researchers found that the median teamwork climate score was higher after than before the intervention only for the 77 nurses among 155 professionals who completed pre- and postintervention surveys (median score, 88.0 versus 80.0). Among the 3,773 patients, the percentage with at least one adverse event was higher after than before the intervention (change, 1.61 percentage points) in control units. Compared with before the intervention, the percentage of patients with at least one adverse event after the intervention was similar in intervention units (change, 0.43 percentage points). No significant difference in change was seen in a difference-in-differences analysis. No differences were seen in length of stay, readmissions, or patient experience.
"Health care leaders should consider our findings in the context of their improvement priorities before implementing similar interventions," the authors write.
Abstract/Full Text (subscription or payment may be required)
Source: HealthDay
Posted : 2023-11-02 06:52
Read more
- Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
- Texas Sues NY Doctor for Prescribing Abortion Pill by Telehealth
- Early Adoption of Tobacco 21 Policies Can Avert Premature Mortality
- EPA Bans Two Solvents Linked to Cancer
- FDA Approves Crenessity (crinecerfont) for the Treatment of Children and Adults with Classic Congenital Adrenal Hyperplasia
- Lower Levels of Total Cholesterol Seen in More Recent Birth Cohorts
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions